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Abstract Type 1 diabetes (T1D) is a metabolic disease
that results from the autoimmune attack against insulin-
producing b-cells in the pancreatic islets of Langerhans.
Currently, there is no treatment to restore endogenous
insulin secretion in patients with autoimmune diabetes. In
the last years, the development of new therapies to induce
long-term tolerance has been an important medical health
challenge. Apoptosis is a physiological mechanism that
contributes to the maintenance of immune tolerance.
Apoptotic cells are a source of autoantigens that induce
tolerance after their removal by antigen presenting cells
(APCs) through a process called efferocytosis. Efferocytosis
will not cause maturation in dendritic cells, one of the most
powerful APCs, and this process could induce tolerance
rather than autoimmunity. However, failure of this mecha-
nism due to an increase in the rate of b-cells apoptosis and/or
defects in efferocytosis results in activation of APCs, con-
tributing to inflammation and to the loss of tolerance to self.
In fact, T1D and other autoimmune diseases are associated
to enhanced apoptosis of target cells and defective apoptotic
cell clearance. Although further research is needed, the
clinical relevance of immunotherapies based on apoptosis
could prove to be very important, as it has translational
potential in situations that require the reestablishment of
immunological tolerance, such as autoimmune diseases.
This review summarizes the effects of apoptosis of b-cells
towards autoimmunity or tolerance and its application in the
field of emerging immunotherapies.
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Introduction
Type 1 diabetes (T1D) is an autoimmune disease that
permanently destroys the insulin-producing cells in the
pancreatic islets as a consequence of T-lymphocyte medi-
ated autoimmunity. There is a long asymptomatic period -
prediabetic phase- characterized by the production of
autoantibodies specific for islet autoantigens, including
insulin. The inflammatory response in the islet microen-
vironment contributes to the induction and amplification of
the immune attack against pancreatic b-cells and at later
stages, to the stabilization and maintenance of insulitis [1],
mainly composed by T and B cells, but also macrophages,
dendritic cells (DCs), natural killer (NK) cells and natural
killer T (NKT) cells. Moreover, TNF-a and IFN-c pro-
duced by leukocytes in the islet microenvironment may
induce nitric oxide (NO) secretion by b-cells, thus pro-
moting their apoptosis [2]. In this scenario, proinflamma-
tory cytokines and chemokines may contribute to suppress
b-cell function and to induce apoptosis, and also to the
recruitment of antigen presenting cells (APCs) into the
pancreatic islets. These APCs can activate the specific
immune response or act as regulatory cells to maintain
tolerance. The removal of apoptotic b-cells is crucial in this
step. If b-cells are not efficiently cleared in a short period
of time, they will become necrotic, contributing to auto-
immune attack amplification, through autoreactive lym-
phocytes activation. In addition, b-cells from T1D patients
display a low but constant capacity of regeneration [3],
constituting a chronic source of apoptotic b-cells that may
contribute to the proposed model of relapsing-remitting
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T1D [4]. Here we review how apoptotic b-cell clearance
has immunological consequences on disease pathogenesis
and how the design of innovative immunotherapies may be
inspired by apoptosis.
Apoptosis is a crucial process in homeostasis
In the human body, tens of billions of cells continuously
die as a consequence of cell turnover, cell damage, infec-
tion or immunological central tolerance. This physiological
cell death is programmed, and the main mechanism is
called apoptosis [5]. During apoptosis, the cell and nuclei
condense and become fragmented without losing func-
tional integrity of the nuclear envelope and cell membrane.
Morphological characteristics of apoptosis are membrane
blebbing, nuclear fragmentation and chromatin condensa-
tion. This physiological process eliminates unwanted cells,
maintains homeostasis and confers advantages to the
organism.
The small sealed cell fragments resulting from apoptosis
are called apoptotic bodies. This event stands in contrast to
necrosis, which is first marked by a loss of cell membrane
integrity and a release of damage-associated molecules.
The formation of apoptotic bodies is a mechanism for
preventing leakage of potentially toxic or immunogenic
cellular contents of dying cells. Despite the constant turn-
over of cells through apoptosis, apoptotic cells are rarely
seen under physiological conditions because of a high rate
of apoptotic cell clearance by phagocytes. This process is
called efferocytosis, from efferre, which means ‘to take to
the grave’ or ‘to bury’ in Latin. Efferocytosis takes place
without inducing inflammation, with an anti-protease
activity and growth-promoting effects to help in cell
replacement.
Apoptosis and efferocytosis modulate the immune
response
The immune system is one of the most complex networks
of the body. Its main role is to recognize and protect the
organism from invading pathogens, neoplastic cells, and
other dangerous signals, while maintaining tolerance to
self. The first and immediate line of defense to protect the
organism from infection is provided by the innate immune
response, which triggers an inflammatory response and
initiates the response of the adaptive immune system. The
adaptive immune response can distinguish between self/
nonself antigens, being highly specific to each particular
pathogen or dangerous antigen. A key feature of the
adaptive immune system is memory, which confers life-
long immunity to previously encountered pathogens. In
principle, the immune system of a subject does not become
activated against its own tissues, a concept proposed as
horror autotoxicus at the beginning of the twentieth cen-
tury by Paul Ehrlich [6]. However, the complex immuno-
logical network may fail in certain individuals or life
stages, thus allowing the immune system to attack self-
components of the body. This disorder is called autoim-
munity, and can be demonstrated by the presence of
autoantibodies and autoreactive T lymphocytes [7], capable
of transferring the autoimmune reaction [8]. Autoimmunity
is the cause of a broad spectrum of human illnesses, known
as autoimmune diseases.
Dying cells talk to the immune system and alert the
immune system if necessary [5]. If cell death is caused by a
danger-trauma, cancer, infectious disease-, defense and
repair mechanisms are mobilized in the host. However, if cell
death is part of normal physiological processes, the immune
system takes advantage of the cell removal to inhibit immune
responses and to maintain tolerance to self, as demonstrated
in experimental models [9, 10]. Whereas necrotic cells alert
the immune system to respond, apoptotic cells initially
maintain membrane integrity and, if they are rapidly cleared
by phagocytes, these cells do not release danger signals and
the immune system is not stimulated [11]. Therefore, effer-
ocytosis promotes immune tolerance to autoantigens in the
absence of inflammation [12], by keeping an ‘immunologi-
cally silent’ microenvironment [13].
Recent studies provide new findings into the process,
including how APCs process apoptotic cells without
inducing inflammation and maintaining cellular homeo-
stasis [14]. Many receptors, adaptors and chemotactic
molecules are involved in prompt apoptotic cell clearance
[15]. Over the last few years, new insights into the
engulfment process of apoptotic cells by phagocytes have
been reported [5, 16]. In vivo cell clearance is performed
through four steps: firstly, the sensing of the corpses is
done by ‘find me’ signals released by apoptotic cells, such
as chemokines (CX3CL1 [17]), adhesion molecules
(intercellular adhesion molecule 3 (ICAM-3) [18]) and
nucleotides (ATP and UTP [19]), among others. These
signals are recognized by receptors in the membrane of
phagocytes and induce phagocyte migration toward the
apoptotic cell. Also, ‘stay away’ signals have been identi-
fied in order to maintain an anti-inflammatory microenvi-
ronment. In this sense, lactoferrin proteins released by
apoptotic cells inhibit neutrophil recruitment [20]. Sec-
ondly, ‘eat me’ signals exposed on the surface of apoptotic
cells are recognized by phagocyte receptors. One of the
main ‘eat-me’ signals is phosphatidylserine (PS), translo-
cated to the outer leaflet of the lipid bilayer in apoptotic
cells. Many receptors that recognize PS on apoptotic cells
have been described on the surface of phagocyte cells, such
as members of the T cell immunoglobulin mucin domain
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(TIM) protein family including TIM-1 and TIM-4 [21, 22],
the Stabilin-2 [23], the receptor for advanced glycation end
products (RAGE) [24] and the brain-specific angiogenesis
inhibitor 1 (BAI1) [25]. PS may also be recognized indi-
rectly by bridging molecules, such as Gas6 and protein S
through the TAM family of receptors (Tyro-3, Axl, and
Mer) [26]. Other membrane molecules have also been
described to bind apoptotic cells, such as CD36, CD14,
CD68 and aVb3 integrin [27], among others. In addition to
‘eat me’ signals, ‘don’t eat me’ signals, expressed on the
surface of living cells, such as CD47, help phagocytes to
distinguish between alive and dead cells [28]. Thirdly,
signaling pathways regulate cytoskeletal rearrangement for
engulfment, and finally, signaling events within the
phagocytes regulate the processing of apoptotic cell auto-
antigens to induce tolerance to self in an immunologically
silent microenvironment [29].
After efferocytosis, anti-inflammatory mediators are
produced by the APCs—mainly DCs—whereas the release
of inflammatory cytokines is inhibited by avoiding DCs
maturation. DCs are the most professional APCs and
determine immunogenicity or tolerance. DCs play a basic
role in the initiation of the immune response by presenting
antigenic peptides when activated, but in the absence of
inflammation, immature DCs (iDCs) are essential to main-
tain tolerance to self. The capture of apoptotic cells by iDCs
does not cause maturation and maintains peripheral toler-
ance [13, 30]. Moreover, a subset of DCs constantly uptake
apoptotic cells and deliver tolerogenic signals to self in the
lymph node [31]. Therefore, the uptake of apoptotic cells—
which has been proposed to suppress DC immunogenicity—
is a physiological mechanism involved in tolerogenic DCs
(tolDCs) generation (Table 1). TolDCs are effector DCs
capable of inducing peripheral tolerance. It has been shown
that tolDCs loaded with apoptotic cells express low levels of
MHC class II molecules and costimulatory molecules
CD40, CD80 and CD86, even after the exposure to some
proinflammatory stimulus [32, 33], secrete low amounts of
proinflammatory cytokines IL-1a, IL-1b and TNF-a [34]
and decrease their ability to stimulate T cell proliferation
[35]. In addition, efferocytosis may induce DCs to secrete
immunosuppressive mediators, such as TGF-b, which trig-
gers the differentiation of classical regulatory T lympho-
cytes, Foxp3? Tregs [36, 37]. In this sense, the secretion of
IL-10, an anti-inflammatory cytokine, has been found
upregulated in LPS-activated DCs exposed to early apop-
totic cells. Those DCs become impaired to maturate and fail
to activate T cells [38]. Other authors reported that apoptotic
cells could turn DCs to inhibitory DCs, impairing CD4? T
cell proliferation via nitric oxide (NO) production [39, 40].
Efferocytosis may also promote suppressive effects on DCs
through prostaglandin E2 (PGE2) production [41] or via
interferon-c-induced indoleamine 2,3-dioxygenase (IDO)
[42]. It has also been reported that the tolerogenic effect
acquired by DCs after efferocytosis results in tolerance
induction in vivo. For example, the uptake of apoptotic cells
by viable DCs is able to suppress their maturation and
promote tolerance through the induction of Tregs by the
secretion of TGF-b [43] or the expression of programmed
death-ligand 1 (PD-L1) [44]. In the context of transplant
immunology, the administration of donor apoptotic cells
prolonged cardiac allograft survival in mice [45] and
improved chronic allograft vasculopathy [46] through the
interaction with recipient DCs. In addition, recipient DCs
loaded with donor-derived apoptotic cells restrained allo-
recognition in cardiac allograft transplant [47].
In apparent contradiction to these data, apoptotic cells
induce macrophages or DCs activation in some cases. It is well
known that DCs that engulfed infected or tumor apoptotic
cells can induce physiological anti-viral and anti-tumor anti-
gen specific immunity [48]. This fact could be explained by
differences on the antigenic content of harmless or dangerous
apoptotic cells. In fact, several aspects of the apoptotic process
are basic for the subsequent immune modulation [16]: (1) The
‘quality’ of apoptotic cells, which includes the cell type, the
cause of cell death and the activation status of the dying cells.
It determines which type of ‘eat me’ signals is being exposed
to the phagocytes [15]. (2) The ratio of apoptotic cells, which
can determine the magnitude of the resulting immune
response. (3) The apoptotic cell microenvironment that
determines which phagocyte is in charge to mediate clearance
and regulate the immune response. (4) The timing of cell death
and duration of apoptotic cell-derived signals. Therefore, the
specific conditions of apoptosis define if apoptotic cells pro-
mote immunity or induce tolerance.
Apoptosis can be pathological, due to either too much
loss of cells with little regenerative capacity, by too little
apoptotic cell removal or by ineffective apoptotic cell
digestion. These processes are altered in many diseases,
including autoimmune diseases [11]. If apoptotic cells are
not removed or digested within a certain time, they become
late apoptotic cells -called secondary necrotic cells- that
have lost the integrity of the membrane, favoring the
release of intracellular content. In this case, these cells can
promote inflammation and autoimmunity, similar to
necrotic cells. Defects in clearance are believed to have an
important effect on autoimmune diseases, cardiovascular
diseases, neurological diseases, pulmonary diseases,
infection and cancer [49]. Moreover, it has been described
that accumulation of DNA from apoptotic cells -due to an
excess of apoptosis and/or defective degradation mecha-
nisms in the cytoplasm of phagocytes- could induce
excessive type I IFN production [50]. The production of
these cytokines could be a triggering factor in the process
leading to autoimmune diseases in general and to T1D in
particular [51].
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Type 1 diabetes: apoptosis of b-cells and implications
for the disease
T1D is a metabolic disease that results from the autoim-
mune attack against insulin-producing b-cells in the islets
of Langerhans of the pancreas. The islets, taken together,
can be thought of as a single organ occupying 1 % of the
pancreas weight. Each islet contains on average a total of
1,000 cells [52] that secrete hormones related to the glu-
cose homeostasis. Among these, 65–80 % are insulin-
producing b-cells. T1D etiology is unidentified, but it is
known that the disease appears in genetically susceptible
individuals with impaired immune regulation after envi-
ronmental triggers [53]. The onset of the disease is pre-
ceded by a long asymptomatic period named prediabetes.
During this prediabetic stage, islet reactive autoantibodies
arise in the sera and autoreactive T cells start to destroy b-
cells, resulting in a progressive loss in insulin secretory
function. Clinical onset of T1D occurs when 80–90 % of
the b-cells have been destroyed.
Apoptosis of b-cells has been demonstrated to be
involved in autoimmune T1D and type 2 diabetes (T2D), as
in the loss of insulin producing cells after islet transplan-
tation [54]. In T2D abnormal levels of metabolic factors
contribute to the apoptosis after b-cell failure [55]. The
decrease of b-cell mass after islet transplantation can be
due to several factors, including apoptosis triggered by the
stress related to enzymatic islet digestion and purification
[56], and allogeneic graft rejection. T1D is associated to
enhanced b-cells apoptosis and defective clearance. In this
sense, much of our knowledge of the role of apoptosis in
T1D comes from the non obese diabetic (NOD) mouse, a
spontaneous murine model that closely resembles human
T1D [57]. In health conditions, a peak of physiological b-
cell death has been described in mice 2 weeks after birth
[58]. Interestingly, a similar peak of b-cell death has been
described in humans, peaking at the perinatal period, when
the process of islet remodeling has been observed [59].
This wave of physiological b-cell death, which takes place
in all individuals, seems to be very important in the initi-
ation of T1D in genetically predisposed subjects [60]. In
addition to these waves of b-cell death, several factors may
promote b-cell apoptosis such as cytokines, glucose,
hypoxia and different forms of stress [61]. Prolonged
exposure of pancreatic b-cells to proinflammatory cyto-
kines induces the expression of miRNAs that contribute to
b-cell dysfunction and apoptosis during the early asymp-
tomatic stages of autoimmunity [62]. Therefore, the wave
of physiological b-cell death is crucial in the initiation of
T1D, due to either too much loss of cells with little
regenerative capacity or by too little apoptotic cell removal
[60]. If these dying b-cells are not efficiently removed, they
release danger signals that may activate DCs promoting
insulitis progression and diabetes onset in NOD mice [63].
It has been proposed that the initiation of the disease
occurs in the islets of the pancreas, where under undefined
pathogenic conditions, b-cell antigens are released. The
alterations in the pancreatic islets in humans at T1D onset
have been described in a small number of observations
from autopsies [64, 65] and few pancreatic biopsies of T1D
patients [66]. Interestingly, increased Fas expression was
identified in b-cells of inflamed human islets, which can
Table 1 Characteristics of tolerogenic DCs generated by efferocytosis
Characteristics Effect DCs source (mice/human) Bibliography




BMDCs (C57BL/6, BALB/c, NOD mice)
and splenic DCs (BALB/c mice)/MoDCs
(healthy donors)
[32, 33, 35, 44, 71]
Low IL-1a, IL-1b, IL-6 and TNF-a profile Non-inflammatory
microenvironment
BMDCs (C57BL/6, C57BL/10, NOD
mice)
[32, 34, 71]
Increased PGE2 secretion Suppression of T cell
proliferation
BMDCs (NOD mice) [41]
Increased TGF-b secretion Induction of Tregs BMDCs (C57BL/6, BALB/c mice) [37, 36, 43]
Increased NO production Suppression of T cell
proliferation
BMDCs (C57BL/6, BALB/c mice) [39, 40]
Increased IDO expression Suppression of T cell
proliferation
MoDCs (healthy donors) [42]
Increased IL-10 secretion Anti-inflammatory MoDCs (healthy donors) [38, 93]
Increased PD-L1 expression Induction of Tregs Splenic DCs (BALB/c mice) [44]
Stability LPS maturation resistance BMDCs (C57BL/6, BALB/c, NOD
mice)/MoDCs (healthy donors)
[32, 33, 36, 37, 38,
41]
DCs dendritic cells, BMDCs bone marrow-derived dendritic cells, NOD non obese diabetic, MoDCs monocyte-derived dendritic cells, TNF
tumor necrosis factor, PGE2 prostaglandin E2, TGF transforming growth factor, NO nitric oxygen, IDO indoleamine 2,3-dioxygenase, PD-L1
programmed death-ligand 1, LPS lipopolysaccharide
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induce apoptosis after binding to its receptor [67]. In this
sense, differential expression of genes related to apoptosis
has been reported in human pancreases from T1D patients
[65, 68]. These changes sensitize b-cells to proapoptotic
signals (e.g., cytokines), modulating apoptosis in preclini-
cal T1D autoimmunity. By contrast, islets from T1D
patients also showed down-regulation of pro-apoptotic
genes: MLLT11, PRUNE2 and NLRP1, probably reflecting
an attempt to arrest b-cell apoptosis. Therefore, the pro-
gression towards T1D derives from the imbalance between
increased b-cell death and deficient maintenance of b-cell
mass.
Efferocytosis of b-cells is critical in autoimmune
diabetes
Apoptotic b-cells are the most important source of auto-
antigens in T1D. A high rate of b-cell apoptosis or defects
in the removal of apoptotic cells in pre-diabetes contribute
to autoimmunity [60], because these cells turn into late
apoptotic bodies and secondary necrotic cells, favoring
inflammation, insulitis and autoimmunity (Fig. 1).
In the NOD mouse model, a deficiency in the clearance
of apoptotic cells by macrophages has been described [69].
The accumulation of apoptotic cells results in necrosis,
favoring inflammation and recruitment of macrophages,
DCs, and T cells to the islets, thus exacerbating autoim-
mune damage. It has been reported that a low but constant
capacity of regeneration of b-cells exists in longstanding
T1D patients [3]. This suggests a relapsing-remitting nature
of the disease [4]. In this sense, b-cell regeneration could
have a dual role in T1D, trying to recover b-cell mass but
promoting the autoimmune process through a defective
efferocytosis, leading to diabetes in a vicious cycle.
As it has been previously mentioned, DCs play a dual
role in the immune system. Therefore, how can iDCs
induce tolerance to autoantigens after apoptotic b-cells
efferocytosis? The low levels of costimulatory molecules
in the DC (CD80, CD86), the possibility of a subset of DCs
specialized in tolerance induction, the anti-maturation
cytokine profile, and the expansion of regulatory T cells
could be key factors in maintaining tolerance to autoanti-
gens from apoptotic cells generated during the normal
tissue turnover [70]. Our group has shown that after the
uptake of apoptotic b-cells, DCs displayed a molecular
switch to a tolerogenic phenotype impairing the progress of
insulitis in the NOD mouse, resulting in the prevention of
the disease [71]. DCs loaded with apoptotic b-cells
diminish the expression of costimulatory molecules CD40
and CD86, secrete low amounts of proinflammatory cyto-
kines and acquire impaired ability to stimulate autologous
T cell proliferation, even after proinflammatory stimuli,
thus demonstrating their stability [41]. The initial events
leading to DC activation in T1D are still unknown, but
evidence points to a complex interaction between cyto-
kines, chemokines, costimulatory molecules, inflammatory
mediators, b-cell cytotoxicity and regeneration, and
attempts of immunoregulation in the islet microenviron-
ment [72]. The b-cell apoptosis/clearance rate would be
decisive in DC activation and insulitis progression.
The suppressive function of DCs acquired after effero-
cytosis is a key feature in the maintenance of tolerance to
self. After uptake of apoptotic cells, DCs suppress T cell
proliferation induced by mature DC, thus indicating the
existence of an active suppressor mechanism involving
PGE2 production [73]. PGE2 is a lipid mediator produced
by the liberation of arachidonic acid from cell membrane
phospholipids that has been generally designed to modulate
inflammation, promoting local vasodilatation and local
attraction and activation of innate immune cells at early
stages of inflammation. However, PGE2 also has a sup-
pressive function that limits inflammation [74] to protect
against immunity to self-antigens. In agreement with this, it
has been proposed that PGE2 is released during tissue
injury and inflammation to protect against immunity to self
antigens [75]. In context of T1D, efferocytosis promotes
suppressive effects on DCs through PGE2 production [41].
Moreover, PGE2 levels were found significantly higher in
T1D patients [76], maybe as a response to the inflammation
in an immunoregulatory attempt.
Efficient efferocytosis by DCs and other APCs involves
‘stay away’ signals to inhibit neutrophil recruitment. One
of these signals is transferrin, an iron binding protein. In
fact, transferrin administration protects against disease in
NOD mice [77]. In humans, a decrease in transferrin levels
was described in the sera of newly diagnosed T1D patients.
Moreover, neutrophil recruitment observed in the pancreas
of donors with T1D [78] is controlled by the overexpres-
sion of neutrophil attracting chemokines (CXCL1,
CXCL2) [65, 79]. The cross talk between neutrophils-
recruited in a defective process of apoptotic cell clearance-,
B-1a and plasmacytoid DCs leads to autoimmune diabetes
in NOD mice [80]. Therefore, we hypothesize that defects
in ‘stay away’ signals in early b-cells efferocytosis may
contribute to the loss of tolerance.
Genetics of b-cells apoptosis: additional genetic
susceptibility factors in type 1 diabetes?
There is a strong genetic susceptibility component in T1D:
50 % of the genetic predisposition is due to polymorphisms
in the HLA class II region (named IDDM1) in chromosome
6. Genome-wide association studies (GWAS) have identi-
fied more than 50 loci associated with genetic risk of type
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T1D. In addition to HLA genes, other loci associated to
T1D are the human insulin promoter that controls the
expression of insulin (IDDM2) and immune-related genes
such as PTPN22, CTLA-4, IL2RA, IFIH1, among others
(named IDDM3 to IDDM18) [81]. Most of these genes
have immunological functions, whereas some have meta-
bolic functions, but the exact mechanisms by which these
loci confer susceptibility to T1D remain elusive. New T1D
susceptibility regions can be continuously identified
through association studies (T1Dbase, www.t1dbase.org).
Because apoptosis is a key factor in T1D, there might be
a link between genetic alterations or polymorphisms in the
apoptosis machinery and the pathogenesis of the disease.
Although no genetic defects in apoptosis pathways have
been specifically identified in T1D, functional assays
demonstrate increased apoptosis attributable to the multiple
pathways of this type of cell death and several suscepti-
bility genes have been reported. In this sense, genes linked
to T1D are caspase 7 (CASP7), phosphatase and tensin
homolog (PTEN), small ubiquitin-like modifier (SUMO),
nitric oxide synthase-2 (NOS2) and apolipoprotein CIII
(APOC3) genes [82]. These gene products are important
for apoptosis induction (CASP7 and PTEN), and regulation
(SUMO), for NO production and apoptosis of b-cells
(NOS2), and for promoting apoptosis through increasing
calcium concentration (APOC3). Moreover, recent studies
indicate that important genetically regulated pathways in b-
cells involve genes related to b-cell susceptibility to
apoptosis. One of these genes, protein tyrosine phospha-
tase, non-receptor type 2 (PTPN2), regulates cytokine-
induced apoptosis and may thereby contribute to the
pathogenesis of T1D [83, 84]. Another candidate is the
Fig. 1 Schematic representation of b-cells apoptosis and efferocyto-
sis in type 1 diabetes. b-cells that undergo apoptosis are recognized
and phagocytosed by APCs, leading to physiologic tolerance induc-
tion. However, an increase in the rate of b-cells apoptosis rate and/or
defects in efferocytosis result in the activation of APCs, contributing
to inflammation, to the lack of tolerance to self and to autoimmune
disease. Strategies of immunointervention based on apoptosis, such as
apoptotic cell administration or tolDCs-pulsed with apoptotic b-cells-
could help to the reestablishment of immunological tolerance to b-
cells autoantigens, lost in type 1 diabetes
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cathepsin H (CTSH) gene that exerts its antiapoptotic
effects through reduced expression of proapoptotic factors
Bim, DP5 and c-Myc [85]. Also, basic leucine zipper
transcription factor 2 (BACH2) has been associated to
genetic risk of developing autoimmune diabetes [86]. This
gene regulates proinflammatory cytokine induced apoptosis
in b-cells by cross talking with PTPN2. Besides, gli-similar
3 (GLIS3) may favor b-cell apoptosis by modulating the
alternative splicing of the proapoptotic BH3-only protein
Bim and exacerbating the formation of the most proapop-
totic variant BimS [87, 88].
In the context of islet autoimmunity, there is a cross talk
between inflammation, adaptive immunity and b-cells,
influenced by genetic polymorphisms that affect b-cells
gene expression and amplify apoptosis or diminish anti-
apoptotic signals [89]. A possibility is that subjects carry-
ing these candidate genes can display enhanced b-cell
apoptosis and consequently, defective apoptotic cell
clearance or secondary necrosis. These defects are detri-
mental for apoptosis-induced self-tolerance, resulting in the
activation of APCs and the presentation of autoantigens to
the immune system. This may permit the loss of tolerance
and the activation of autoreactive T lymphocytes thus
potentially amplifying b-cell death and insulitis and con-
tributing to autoimmunity. The correlations between
genotypes and phenotypes suggest an association between
polymorphisms, tendency to b-cell apoptosis and suscep-
tibility to T1D, but further studies are required to confirm
that these genes play pathogenic roles in autoimmune
diabetes. Understanding the genes responsible for b-cell
apoptosis -but also to neogenesis and regeneration- may
lead to the understanding of the imbalanced apoptosis rate
in prediabetes and during hyperglycemia and may help to
the development of new therapies to treat and prevent the
disease.
Use of apoptotic cells in emerging immunotherapies
for type 1 diabetes
During the last years, considerable efforts have been made
in generating new immunotherapies for T1D. However, no
therapy has yet been able to prevent or cure human T1D.
Ideally, a T1D immunotherapy should inhibit autoimmune
attack against b-cells, avoiding systemic side effects and
allowing tissue regeneration.
Apoptotic cells display inherent immunomodulatory
properties useful to design antigen-specific immunothera-
pies in experimental models of T1D. Evidence linking
apoptosis and tolerance has been found in several studies
where the administration of autologous apoptotic cells led
to tolerance induction in models of inflammation, such as
inflammatory arthritis [90], induced lung inflammation
[91, 92] or sepsis [40]. When engulfed by APCs, such as
DCs, apoptotic cells contribute to the maintenance of self-
tolerance through presentation of autoantigens in an active
suppressive process that constitutes a silencer event [93].
The physiological uptake of apoptotic b-cells by DCs
induces a preventive effect in experimental T1D [94]. In
fact, transfusion of apoptotic islet cells decreased diabetes
incidence in NOD mice [95], supporting the suppressor
role of apoptotic cells. The administration of islet apop-
totic cells loaded into tolDCs is another strategy to restore
tolerance to insulin producing cells that prevents T1D in
NOD mice [71]. Apoptotic cell engulfment promotes
molecular and functional changes in DCs towards a tol-
erogenic phenotype in the context of T1D [41]. Gene
expression profile of DCs from NOD mice that capture
islet cell apoptotic bodies showed a downregulation of
genes involved in antigen presentation and differential
expression of cytokines, chemokines, natural immunity
and immunoregulation genes, together with the presence
of specific transcripts for T1D autoantigens. Autologous T
cell proliferation decreases after the capture of apoptotic
cells by DCs, together with a fall of proinflammatory, Th1
and Th17 cytokine secretion, even after a proinflammatory
stimulus. Suppressive function of DCs acquired after ef-
ferocytosis of b-cells in NOD mice is mediated, at least in
part, by PGE2, as previously mentioned. In summary, DCs
can be programmed to induce specific immune tolerance
to b-cells using apoptotic cells, constituting a rational
strategy for a variety of autoimmune conditions. Several
authors have generated tolerogenic DCs capable of mod-
ulating autoimmunity in experimental T1D [96]. In the
clinical setting, a phase I trial has assessed tolerogenic
DCs safety in T1D patients with good results [97].
However, the process of obtaining of apoptotic bodies
from b-cells is very complex and an alternative source is
required.
We are fully conscious that the NOD mouse strain has
some immunological differences compared to human T1D.
However, experimental models are relevant for dissecting
tolerance mechanisms and to test experimental immuno-
therapies. Obviously, caution is needed when translating
results from animal models to a clinical setting. First,
diabetic patients do not share all the immune defects
existing in the NOD mouse. Second, human b-cells are less
able to regenerate than rodent b-cells. Third, NOD mice,
unlike humans, are genetically identical. An important pre-
clinical step will be the assessment of the in vitro effects of
the apoptosis-based immunotherapies in human cells DCs
from diabetic patients. In any case, efforts should be put
into guiding translational research to successful clinical
therapy for T1D.
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Conclusions
The efficient clearance of apoptotic b-cells by APCs in the
islet microenvironment is crucial for the maintenance of
tolerance to self. The interaction between the most pro-
fessional APCs—DCs—and apoptotic b-cells is complex
but it is well accepted that it contributes to the maintenance
of self-tolerance. The breakdown of tolerance to b-cells is
the cause of T1D, an autoimmune disease mediated by
pathogenic T cells. As outlined in this review, an increase
in the number of apoptotic b-cells—physiological or
induced by stress in the islets—together with an inefficient
efferocytosis further facilitate the loss of tolerance to T1D
autoantigens and subsequent specific attack to the b-cells.
Detailed knowledge of the mechanisms involved in an
efficient efferocytosis may contribute to the development
of innovative immunotherapies aimed to recover tolerance
to self in autoimmune diseases, such as T1D.
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